Canada Vigilance Program: Adverse Reaction Monitoring in Canada

被引：0

作者：

Leung, Aaron ^{[1
]}

机构：

[1] Hlth Canada, Toronto, ON, Canada

来源：

CANADIAN JOURNAL OF HOSPITAL PHARMACY | 2008年 / 61卷

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：34 / 35

页数：2

共 50 条

[1] The Canadian Adverse Drug Reaction Monitoring Program has been renamed ’Canada Vigilance’
[J]. Reactions Weekly, 2007, 1175 (1) : 3 - 3
[2] The Canadian Adverse Drug Reaction Monitoring Program has been renamed as Canada Vigilance
[J]. Reactions Weekly, 2008, 1184 (1) : 2 - 2
[3] Social Impact of Adverse Drug Reactions in the Canada Vigilance Program
Castillon, Genaro
Moride, Yola
Salvo, Francesco
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 387 - 388
[4] Growing support for the Canada Vigilance Program
[J]. Reactions Weekly, 2010, 1299 (1) : 3 - 3
[5] Adverse reaction reporting in Canada - 2005
[J]. Reactions Weekly, 2006, 1097-1098 (1) : 3 - 3
[6] ADVERSE VACCINE REACTION SURVEILLANCE IN CANADA
不详
[J]. CANADIAN FAMILY PHYSICIAN, 1992, 38 : 2812 - 2812
[7] Annual report of all ARs reported to Canada Vigilance Program in 2021
[J]. Reactions Weekly, 2022, 1936 (1) : 2 - 2
[8] Vigilance of Cannabis Products in Canada
Jack, S.
[J]. DRUG SAFETY, 2019, 42 (10) : 1231 - 1231
[9] Pragmatic pharmacoeconomic analyses by using post-market adverse drug reaction reports: an illustration using infliximab, adalimumab, and the Canada vigilance adverse reaction database
Maity, Tuhin
Longo, Christopher
[J]. BMC HEALTH SERVICES RESEARCH, 2021, 21 (01)
[10] Pragmatic pharmacoeconomic analyses by using post-market adverse drug reaction reports: an illustration using infliximab, adalimumab, and the Canada vigilance adverse reaction database
Tuhin Maity
Christopher Longo
[J]. BMC Health Services Research, 21

← 1 2 3 4 5 →